Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1953 4
1954 3
1955 3
1957 3
1958 2
1959 3
1960 3
1961 4
1962 5
1963 7
1964 7
1965 4
1966 3
1967 1
1968 5
1969 7
1970 5
1971 8
1972 5
1973 3
1974 5
1975 7
1976 6
1977 5
1978 6
1979 2
1980 6
1981 3
1982 5
1983 7
1984 2
1985 2
1986 4
1987 2
1988 6
1989 10
1990 6
1991 10
1992 4
1993 16
1994 16
1995 10
1996 2
1997 6
1998 11
1999 2
2000 9
2001 5
2002 2
2003 11
2004 15
2005 13
2006 17
2007 9
2008 17
2009 19
2010 30
2011 28
2012 34
2013 40
2014 37
2015 36
2016 46
2017 44
2018 49
2019 63
2020 81
2021 95
2022 97
2023 84
2024 96
2025 109

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,191 results

Results by year

Filters applied: . Clear all
Page 1
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.
Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Van Dao T, De Toni EN, Rimassa L, Breder V, Vasilyev A, Heurgué A, Tam VC, Mody K, Thungappa SC, Ostapenko Y, Yau T, Azevedo S, Varela M, Cheng AL, Qin S, Galle PR, Ali S, Marcovitz M, Makowsky M, He P, Kurland JF, Negro A, Sangro B. Abou-Alfa GK, et al. Among authors: van dao t. NEJM Evid. 2022 Aug;1(8):EVIDoa2100070. doi: 10.1056/EVIDoa2100070. Epub 2022 Jun 6. NEJM Evid. 2022. PMID: 38319892 Clinical Trial.
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK, Galle PR, Rimassa L, Heurgué A, Tam VC, Van Dao T, Thungappa SC, Breder V, Ostapenko Y, Reig M, Makowsky M, Paskow MJ, Gupta C, Kurland JF, Negro A, Abou-Alfa GK; HIMALAYA investigators. Sangro B, et al. Among authors: van dao t. Ann Oncol. 2024 May;35(5):448-457. doi: 10.1016/j.annonc.2024.02.005. Epub 2024 Feb 19. Ann Oncol. 2024. PMID: 38382875 Free article. Clinical Trial.
Sarcopenia and Muscle Aging: A Brief Overview.
Dao T, Green AE, Kim YA, Bae SJ, Ha KT, Gariani K, Lee MR, Menzies KJ, Ryu D. Dao T, et al. Endocrinol Metab (Seoul). 2020 Dec;35(4):716-732. doi: 10.3803/EnM.2020.405. Epub 2020 Dec 23. Endocrinol Metab (Seoul). 2020. PMID: 33397034 Free PMC article. Review.
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC.
Rimassa L, Chan SL, Sangro B, Lau G, Kudo M, Reig M, Breder V, Ryu MH, Ostapenko Y, Sukeepaisarnjaroen W, Varela M, Tougeron D, Crysler OV, Bouattour M, Van Dao T, Tam VC, Faccio A, Furuse J, Jeng LB, Kang YK, Kelley RK, Paskow MJ, Ran D, Xynos I, Kurland JF, Negro A, Abou-Alfa GK. Rimassa L, et al. Among authors: van dao t. J Hepatol. 2025 Oct;83(4):899-908. doi: 10.1016/j.jhep.2025.03.033. Epub 2025 Apr 11. J Hepatol. 2025. PMID: 40222621 Free article. Clinical Trial.
Design of high-specificity binders for peptide-MHC-I complexes.
Liu B, Greenwood NF, Bonzanini JE, Motmaen A, Meyerberg J, Dao T, Xiang X, Ault R, Sharp J, Wang C, Visani GM, Vafeados DK, Roullier N, Nourmohammad A, Scheinberg DA, Garcia KC, Baker D. Liu B, et al. Among authors: dao t. Science. 2025 Jul 24;389(6758):386-391. doi: 10.1126/science.adv0185. Epub 2025 Jul 24. Science. 2025. PMID: 40705892
Loss of SREBP-1c ameliorates iron-induced liver fibrosis by decreasing lipocalin-2.
Lee EH, Lee JH, Kim DY, Lee YS, Jo Y, Dao T, Kim KE, Song DK, Seo JH, Seo YK, Seong JK, Moon C, Han E, Kim MK, Ryu S, Shin M, Roh GS, Jung HR, Osborne TF, Ryu D, Jeon TI, Im SS. Lee EH, et al. Among authors: dao t. Exp Mol Med. 2024 Apr;56(4):1001-1012. doi: 10.1038/s12276-024-01213-2. Epub 2024 Apr 16. Exp Mol Med. 2024. PMID: 38622198 Free PMC article.
Effect of Prophylactic Antibiotics on Mortality in Severe Alcohol-Related Hepatitis: A Randomized Clinical Trial.
Louvet A, Labreuche J, Dao T, Thévenot T, Oberti F, Bureau C, Paupard T, Nguyen-Khac E, Minello A, Bernard-Chabert B, Anty R, Wartel F, Carbonell N, Pageaux GP, Hilleret MN, Moirand R, Nahon P, Potey C, Duhamel A, Mathurin P. Louvet A, et al. Among authors: dao t. JAMA. 2023 May 9;329(18):1558-1566. doi: 10.1001/jama.2023.4902. JAMA. 2023. PMID: 37159035 Free PMC article. Clinical Trial.
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Lau G, Abou-Alfa GK, Cheng AL, Sukeepaisarnjaroen W, Van Dao T, Kang YK, Thungappa SC, Kudo M, Sangro B, Kelley RK, Furuse J, Park JW, Sunpaweravong P, Fasolo A, Yau T, Kawaoka T, Azevedo S, Reig M, Assenat E, Yarchoan M, He AR, Makowsky M, Gupta C, Negro A, Chan SL. Lau G, et al. Among authors: van dao t. J Hepatol. 2025 Feb;82(2):258-267. doi: 10.1016/j.jhep.2024.07.017. Epub 2024 Jul 31. J Hepatol. 2025. PMID: 39089633 Free article. Clinical Trial.
1,191 results